Hepatocellular Carcinoma (HCC) Clinical Trials in Nanjing, Jiangsu
6 recruitingNanjing, Jiangsu, China
Showing 1–6 of 6 trials
Recruiting
Phase 1
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
Unresectable Hepatocellular Carcinoma (HCC)Hepatoma
Suzhou Mednovo Yi Medical Technology Co., Ltd.40 enrolled8 locationsNCT07391839
Recruiting
Phase 2
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Hepatocellular Carcinoma (HCC)
Abbisko Therapeutics Co, Ltd141 enrolled51 locationsNCT07327034
Recruiting
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without TACE for Advanced HCC with Vascular Invasions
Hepatocellular Carcinoma (HCC)
Zhongda Hospital1,200 enrolled1 locationNCT06881446
Recruiting
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without HAIC for Advanced HCC
Hepatocellular Carcinoma (HCC)
Zhongda Hospital900 enrolled1 locationNCT06881433
Recruiting
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
Hepatocellular Carcinoma (HCC)
Zhongda Hospital300 enrolled2 locationsNCT06876753
Recruiting
Phase 2
Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
Hepatocellular Carcinoma (HCC)Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation
The First Affiliated Hospital with Nanjing Medical University276 enrolled1 locationNCT06762782